This article has Open Peer Review reports available.
Clinical characteristics and cerebrospinal fluid parameters in patients with peripheral facial palsy caused by Lyme neuroborreliosis compared with facial palsy of unknown origin (Bell's palsy)
© Bremell and Hagberg; licensee BioMed Central Ltd. 2011
Received: 10 June 2010
Accepted: 10 August 2011
Published: 10 August 2011
Bell's palsy and Lyme neuroborreliosis are the two most common diagnoses in patients with peripheral facial palsy in areas endemic for Borrelia burgdorferi. Bell's palsy is treated with corticosteroids, while Lyme neuroborreliosis is treated with antibiotics. The diagnosis of Lyme neuroborreliosis relies on the detection of Borrelia antibodies in blood and/or cerebrospinal fluid, which is time consuming. In this study, we retrospectively analysed clinical and cerebrospinal fluid parameters in well-characterised patient material with peripheral facial palsy caused by Lyme neuroborreliosis or Bell's palsy, in order to obtain a working diagnosis and basis for treatment decisions in the acute stage.
Hospital records from the Department of Infectious Diseases, Sahlgrenska University Hospital, for patients with peripheral facial palsy that had undergone lumbar puncture, were reviewed. Patients were classified as Bell's palsy, definite Lyme neuroborreliosis, or possible Lyme neuroborreliosis, on the basis of the presence of Borrelia antibodies in serum and cerebrospinal fluid and preceding erythema migrans.
One hundred and two patients were analysed; 51 were classified as Bell's palsy, 34 as definite Lyme neuroborreliosis and 17 as possible Lyme neuroborreliosis. Patients with definite Lyme neuroborreliosis fell ill during the second half of the year, with a peak in August, whereas patients with Bell's palsy fell ill in a more evenly distributed manner over the year. Patients with definite Lyme neuroborreliosis had significantly more neurological symptoms outside the paretic area of the face and significantly higher levels of mononuclear cells and albumin in their cerebrospinal fluid. A reported history of tick bite was uncommon in both groups.
We found that the time of the year, associated neurological symptoms and mononuclear pleocytosis were strong predictive factors for Lyme neuroborreliosis as a cause of peripheral facial palsy in an area endemic for Borrelia. For these patients, we suggest that ex juvantibus treatment with oral doxycycline should be preferred to early corticosteroid treatment.
Peripheral facial palsy occurs in the general population, with an annual incidence of 20-53 per 100,000 [1, 2]. In areas endemic for Borrelia burgdorferi (Bb), Lyme neuroborreliosis (LNB) is estimated to cause 2-25% of peripheral facial palsy cases [3–6]. The remaining cases are caused by a wide range of diagnoses, such as Ramsay Hunt syndrome, sarcoidosis, Sjögren's syndrome, tumours and acute idiopathic peripheral facial palsy, also known as Bell's palsy (BP). Of these, BP constitutes by far the largest group, causing 60-75% of cases of peripheral facial palsy [2, 7]. While LNB is treated with oral doxycycline or intravenous ceftriaxone, early treatment (within 72 hours) with corticosteroids improves the outcome in BP [8–12]. In order to choose the right treatment, it is important to differentiate between these two conditions. Antibodies to Bb in serum and cerebrospinal fluid (CSF) are often helpful in the diagnosis, but it generally takes a couple of days to obtain the analysis results. Furthermore, no data are available regarding the optimal treatment of patients with BP who present more than 72 hours after the onset of symptoms . At the time of admission, the treatment decision must therefore frequently be based on patient history, physical examination and cerebrospinal fluid analysis of leukocytes, albumin and glucose, which can be obtained within hours. There is no time to wait for the results of other analyses. The aim of this study was retrospectively to analyse clinical and CSF parameters in well-characterised patient material with LNB and BP, where an acute lumbar puncture had been performed, in order to obtain a base for treatment decisions.
Hospital records for all the patients that presented at, or were referred to, the Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden, with peripheral facial palsy and in whom a lumbar puncture had been performed, between February 2000 and February 2009, were reviewed. Data on specific medical history, clinical characteristics and laboratory parameters were collected. Patients with peripheral facial palsy with causes other than LNB or BP were excluded.
Patients were classified as BP, definite LNB, or possible LNB. Patients with Bb antibodies below the upper reference level in both serum and CSF, and with no history of erythema migrans (EM) within 3 months before the onset of neurological symptoms and with no other causes of peripheral facial palsy, were classified as BP. Patients with Bb antibodies (IgG and/or IgM) above the upper reference level in CSF and either a positive Bb antibody index or the presence of ≥ 2 oligoclonal bands on isoelectric focusing of CSF and serum, or with a history of EM within 3 months before the onset of neurological symptoms, were classified as definite LNB. Patients with Bb antibodies above the upper reference level in CSF and/or serum but with a negative Bb antibody index and < 2 oligoclonal bands on isoelectric focusing of CSF and serum and with no history of EM within 3 months before the onset of neurological symptoms were classified as possible LNB. The Bb antibody index was calculated as the ratio of the CSF/serum quotient of specific antibodies to the corresponding CSF/serum quotient of total immunoglobulins. Antibody index values of > 1.4 were considered positive .
For clarity, comparisons of clinical characteristics and laboratory parameters were made mainly between the definite LNB and BP groups, with the possible LNB group described in more detail separately. CSF pleocytosis was deliberately not used as a diagnostic criterion, since one aim of the study was to analyse differences in CSF parameters between the groups.
A subgroup analysis was made of patients with peripheral facial palsy without associated neurological symptoms.
Two different tests were used to analyse Bb antibodies in serum and CSF during the study period. Until 26 June 2006, antibodies were analysed using an enzyme-linked immunosorbent assay (ELISA) kit for IgG and IgM antibodies (Dako Lyme Borreliosis Kit, Dako). Tests positive for IgM were further analysed with a more specific test (IDEIA, Dako). After 26 June 2006, Bb antibodies were analysed using a sandwich chemiluminescence immunoassay (CLIA) test kit (LIASON, DiaSorin).
Results were analysed using a statistical software package (PASW Statistics 18.0). For the analysis of unpaired categorical data, Pearson's χ2 test was used. As the quantitative measures showed a markedly skewed distribution, they were analysed using the non-parametric Mann-Whitney U test. Quantitative variables are presented as the median (range). p-values of < 0.05 were considered statistically significant.
The study was approved by the Regional Ethical Review Board, Gothenburg, Sweden.
Hospital records for 109 patients were reviewed. Seven patients diagnosed with diseases other than LNB or BP were excluded (5 patients with Ramsay Hunt syndrome, 1 with brain stem infarction, 1 with erysipelas). In all, 102 patients were analysed; 51 were classified as BP, 34 as definite LNB and 17 as possible LNB. Of the patients diagnosed as definite LNB, 30 had a positive Bb antibody index. Of the remaining 4 patients, 2 had ≥ 2 oligoclonal bands (IgG or IgM) on isoelectric focusing of CSF and serum, while 2 had a preceding EM.
Baseline data, clinical characteristics and CSF laboratory data
(n = 51)
(n = 34)
(n = 17)
Tick bite within 3 months
Local pain, affected side of face
Radiculitic pain, other location
Local sensibility disturbances
Other sensibility disturbances
No associated neurogical symptoms
Duration of symptoms before LP, days
CSF laboratory data
Mononuclear cells, no/μL
All the patients in the definite LNB group had an elevated number of CSF mononuclear cells (ref. < 5/μL), compared with 20% in the BP group. The median CSF mononuclear cell count in the definite LNB group was 165/μL (32-1044), while it was 2/μL (0-534) in the BP group (p < 0.001). CSF albumin levels were also significantly higher in the definite LNB group, median 840 mg/L (197-2850), than in the Bell's palsy group, median 196 mg/L (76-768) (p < 0.001) (Table 1).
The patients in the possible LNB group did not differ significantly from the patients in the BP group in any of the clinical characteristics or laboratory parameters described above. However, they differed significantly from the definite LNB patients in neurological symptoms outside the affected area of the face, radiculitic pain (6% and 50% respectively, p = 0.006) and sensibility disturbances (6% and 24%, p = 0.03), and also in CSF laboratory parameters, mononuclear cells (median 3/μL [0-41] and median 165/μL [32-1044] respectively, p < 0.001), and albumin (median 204 mg/L [66-774] and 840 mg/L [197-2850], p < 0.001) (Table 1).
Subgroup analysis of patients without associated neurological symptoms
(n = 25)
(n = 6)
(n = 7)
Tick bite within 3 months
Duration of symptoms before LP, days
CSF laboratory data
Mononuclear cells, no/μL
Peripheral facial palsy of unknown origin (Bell's palsy) is a disease with a large number of differential diagnoses . In our study, we required evidence of intrathecally produced antibodies or preceding erythema migrans for a definite LNB diagnosis. Intrathecal antibody production is generally used for a definite diagnosis, but it has low sensitivity in the very early phase of the disease . In general, patients with LNB display intrathecally produced antibodies within two weeks of the onset of symptoms, but in some patients antibody production may be delayed for up to six weeks, which poses a diagnostic problem [16, 17]. Furthermore, both the culture of CSF for Bb and the detection of Bb in CSF by specific PCR analysis have a very low sensitivity and are not used in clinical routine . It is therefore difficult completely to rule out the possibility that some patients with LNB were classified as BP, especially since patients diagnosed as BP underwent LP earlier than patients diagnosed as LNB (definite or possible) (Table 1). However, clinical follow-up did not change the diagnosis in any patient with BP. With these diagnostic drawbacks, there will always be some patients for whom the diagnosis is difficult and who will be classified as unknown. On the other hand, using only serum antibodies against Bb as a diagnostic criterion will produce a large number of false positive cases, since the seroprevalence of antibodies against Bb is high in the general population; 7-29% in endemic areas of Sweden [19, 20].
The possible LNB group in the study (who had Bb antibodies in serum but not in CSF and no history of EM) did not differ significantly from the BP patients in terms of clinical characteristics or laboratory parameters and did not, as a median, display mononuclear pleocytosis or elevated albumin in CSF. We interpreted this as a reflection of the high seroprevalence of Bb antibodies in the population, rather than a Bb infection as the aetiology of peripheral facial palsy.
Among the 38 patients without associated neurological symptoms that were analysed as a subgroup, BP patients, as expected, constituted the majority, 66% (n = 25), and patients with possible LNB 18% (n = 7). However, 16% (n = 6) of these patients were diagnosed as definite LNB, showing that the absence of associated neurological symptoms does not exclude LNB as a cause of peripheral facial palsy. The differences in the CSF mononuclear cell count and albumin levels were also significant in the subgroup analysis, underlining the importance of CSF sampling in the diagnosis of LNB.
The observed seasonal variation in the incidence of peripheral facial palsy caused by LNB, with a peak in late summer/early autumn and no cases during late winter/early spring, confirms previous studies and co-varies with the tick-feeding season. The absence of any cases outside that season is also evidence that the incubation period for LNB is rarely more than a couple of weeks, as previously described [3, 5, 6, 21].
The differing clinical picture between peripheral facial palsy caused by LNB and BP, with a higher occurrence of neurological symptoms outside the cranial nerve area in peripheral facial palsy caused by LNB, is broadly in accordance with previous studies. Two small, early studies describe polyneuropathy and radiculitic pain as symptoms that predict LNB, whereas a larger study from 2002 describes headache, arthralgia and enlarged cervical lymph nodes [3, 4, 6]. What is not usually described, however, is the high percentage of patients with BP that describe pain from the affected area of the face (43%).
A reported history of tick bite was uncommon in the definite LNB group (29%). The same low numbers have also been seen in some earlier studies, while other studies have suggested the use of a history of tick bite in discriminating between BP and LNB [5, 22, 23]. It is therefore important to stress that the absence of a tick bite history does not exclude LNB.
The present study was performed at a department, which mainly treats adult patients. Consequently, the age of the patients in this study is not fully representative of all patients with BP or LNB. However, the median ages of the respective groups are similar to those reported previously. Patients with definite LNB were older than patients with BP, median age 46 (7-75) and 36 (15-70) respectively. This is in line with the bimodal age distribution of LNB, with a median in the fifth decade of life and with the reported peak incidence of BP around the second to fifth decade of life [14, 24].
One aim of this study was to analyse differences in CSF parameters between the definite LNB and BP patient groups. It was therefore not possible to use CSF mononuclear pleocytosis as a diagnostic criterion for LNB. In spite of this, we found that time during the year, presence of neurological symptoms outside the affected area of the face and mononuclear pleocytosis in CSF were strong predictive factors for LNB. All these data are possible to obtain within hours after admission, which can be of help in the choice of acute treatment.
We found that the time of the year, associated neurological symptoms and mononuclear pleocytosis in CSF were strong predictive factors for LNB as a cause of peripheral facial palsy in an area endemic for borreliosis. For these patients, we suggest that ex juvantibus treatment with oral doxycycline should be preferred to early corticosteroid treatment.
The study was supported by the Sahlgrenska Academy at the University of Gothenburg (ALFGBG-74100).
- Morris AM, Deeks SL, Hill MD, Midroni G, Goldstein WC, Mazzulli T, Davidson R, Squires SG, Marrie T, McGeer A, Low DE: Annualized incidence and spectrum of illness from an outbreak investigation of Bell's palsy. Neuroepidemiology. 2002, 21: 255-261. 10.1159/000065645.View ArticlePubMedGoogle Scholar
- Finsterer J: Management of peripheral facial nerve palsy. Eur Arch Otorhinolaryngol. 2008, 265: 743-752. 10.1007/s00405-008-0646-4.View ArticlePubMedPubMed CentralGoogle Scholar
- Olsson I, Engervall K, Asbrink E, Carlsson-Nordlander B, Hovmark A: Tick-borne borreliosis and facial palsy. Acta Otolaryngol. 1988, 105: 100-107.View ArticlePubMedGoogle Scholar
- Bjerkhoel A, Carlsson M, Ohlsson J: Peripheral facial palsy caused by the Borrelia spirochete. Acta Otolaryngol. 1989, 108: 424-430. 10.3109/00016488909125548.View ArticlePubMedGoogle Scholar
- Halperin JJ, Golightly M: Lyme borreliosis in Bell's palsy. Long Island Neuroborreliosis Collaborative Study Group. Neurology. 1992, 42: 1268-1270.View ArticlePubMedGoogle Scholar
- Peltomaa M, Pyykko I, Seppala I, Viljanen M: Lyme borreliosis and facial paralysis--a prospective analysis of risk factors and outcome. Am J Otolaryngol. 2002, 23: 125-132. 10.1053/ajot.2002.123434.View ArticlePubMedGoogle Scholar
- Gilden DH: Clinical practice. Bell's Palsy. N Engl J Med. 2004, 351: 1323-1331. 10.1056/NEJMcp041120.View ArticlePubMedGoogle Scholar
- Sullivan FM, Swan IR, Donnan PT, Morrison JM, Smith BH, McKinstry B, Davenport RJ, Vale LD, Clarkson JE, Hammersley V, et al: Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med. 2007, 357: 1598-1607. 10.1056/NEJMoa072006.View ArticlePubMedGoogle Scholar
- Engstrom M, Berg T, Stjernquist-Desatnik A, Axelsson S, Pitkaranta A, Hultcrantz M, Kanerva M, Hanner P, Jonsson L: Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2008, 7: 993-1000. 10.1016/S1474-4422(08)70221-7.View ArticlePubMedGoogle Scholar
- Halperin JJ, Shapiro ED, Logigian E, Belman AL, Dotevall L, Wormser GP, Krupp L, Gronseth G, Bever CT: Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007, 69: 91-102. 10.1212/01.wnl.0000265517.66976.28.View ArticlePubMedGoogle Scholar
- Dotevall L, Hagberg L: Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis. 1999, 28: 569-574. 10.1086/515145.View ArticlePubMedGoogle Scholar
- Ljostad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, Mygland A: Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 2008, 7: 690-695. 10.1016/S1474-4422(08)70119-4.View ArticlePubMedGoogle Scholar
- Reiber H, Lange P: Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem. 1991, 37: 1153-1160.PubMedGoogle Scholar
- Rath B, Linder T, Cornblath D, Hudson M, Fernandopulle R, Hartmann K, Heininger U, Izurieta H, Killion L, Kokotis P, et al: "All that palsies is not Bell's "--The need to define Bell's palsy as an adverse event following immunization. Vaccine. 2007, 26: 1-14. 10.1016/j.vaccine.2007.10.043.View ArticlePubMedGoogle Scholar
- Hansen K, Lebech AM: The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain. 1992, 115 (Pt 2): 399-423.View ArticlePubMedGoogle Scholar
- Hansen K, Lebech AM: Lyme neuroborreliosis: a new sensitive diagnostic assay for intrathecal synthesis of Borrelia burgdorferi--specific immunoglobulin G, A, and M. Ann Neurol. 1991, 30: 197-205. 10.1002/ana.410300212.View ArticlePubMedGoogle Scholar
- European Union Concerted Action on Lyme Borreliosis - Case Definitions. [http://meduni09.edis.at/eucalb/cms/index.php?option=com_content&task=view&id=42&Itemid=58]
- Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP: Diagnosis of lyme borreliosis. Clin Microbiol Rev. 2005, 18: 484-509. 10.1128/CMR.18.3.484-509.2005.View ArticlePubMedPubMed CentralGoogle Scholar
- Dumler JS, Dotevall L, Gustafson R, Granstrom M: A population-based seroepidemiologic study of human granulocytic ehrlichiosis and Lyme borreliosis on the west coast of Sweden. J Infect Dis. 1997, 175: 720-722. 10.1093/infdis/175.3.720.View ArticlePubMedGoogle Scholar
- Gustafson R: Epidemiological studies of Lyme borreliosis and tick-borne encephalitis. Scand J Infect Dis Suppl. 1994, 92: 1-63.PubMedGoogle Scholar
- Kaiser R: Neuroborreliosis. J Neurol. 1998, 245: 247-255. 10.1007/s004150050214.View ArticlePubMedGoogle Scholar
- Engervall K, Carlsson-Nordlander B, Hederstedt B, Berggren D, Bjerkhoel A, Carlborg A, Grenner J, Hanner P, Hogmo A, Isholt RM, et al: Borreliosis as a cause of peripheral facial palsy: a multi-center study. ORL J Otorhinolaryngol Relat Spec. 1995, 57: 202-206. 10.1159/000276740.View ArticlePubMedGoogle Scholar
- Lotric-Furlan S, Cimperman J, Maraspin V, Ruzic-Sabljic E, Logar M, Jurca T, Strle F: Lyme borreliosis and peripheral facial palsy. Wien Klin Wochenschr. 1999, 111: 970-975.PubMedGoogle Scholar
- Huppertz HI, Bohme M, Standaert SM, Karch H, Plotkin SA: Incidence of Lyme borreliosis in the Wurzburg region of Germany. Eur J Clin Microbiol Infect Dis. 1999, 18: 697-703. 10.1007/s100960050381.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/11/215/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.